title: Residual neuromuscular block in type II diabetes mellitus after rocuronium: a prospective observational study.
abstract: BACKGROUND
  Diabetes mellitus causes motor nerve dysfunction and degeneration that may alter the response to neuromuscular blocking drugs.
  
  
  OBJECTIVE
  To analyse the risk of residual neuromuscular block (RNMB) induced by rocuronium given in standard doses to patients with type 2 diabetes mellitus (T2DM).
  
  
  METHODS
  A prospective, observational study.
  
  
  METHODS
  Hospital San Jorge, Huesca and Hospital San Pedro, Logroño, Spain, from December 2011 to June 2012.
  
  
  METHODS
  T2DM patients with no diabetic neuropathy or neurological symptoms (n = 32) and healthy controls (n = 39).
  
  
  METHODS
  All participants received a single dose of rocuronium 0.6 mg kg. Neuromuscular block was monitored throughout surgery until a train of four (TOF) ratio of at least 0.9 was achieved.
  
  
  RESULTS
  Time from rocuronium injection to a TOF ratio of at least 0.9 (DURTOF90).
  
  
  RESULTS
  Time to reappearance of T1, T2, T3 and T4 of TOF; glycosylated haemoglobin values (HbA1c); correlation between blood glucose control and DURTOF90 in the group of diabetic patients.
  
  
  RESULTS
  No significant differences in age, weight, renal function or other characteristics interfering with neuromuscular block were seen between T2DM patients and controls. DURTOF90 was significantly longer in the group of T2DM patients than in the controls (109.86 vs. 84.77 min, P = 0.001). Times to reappearance of T1, T2, T3 and T4 of TOF were also significantly longer in the T2DM group. No correlation was found between HbA1C and DURTOF90 values. In addition, DURTOF90 did not appear to be related to elevated blood glucose levels.
  
  
  CONCLUSIONS
  Diabetic patients, even in the absence of complications, have an increased risk of RNMB after rocuronium administration compared with those without diabetes. Poorer glycaemic control of diabetes does not appear to increase the risk. Appropriate dose and vigilant monitoring of the neuromuscular blocker is helpful in patients with T2DM.
authors.affiliation: From the Department of Anesthesiology, Resuscitation, and Pain Management, Hospital San Jorge, Huesca (IA-B, EM-D, JV-B), Department of Anesthesiology, Surgical Intensive Care, and Pain Management, Hospital San Pedro, Logroño (FL-S, EF-J), Department of Anesthesiology and Critical Care, Hospital Universitario Basurto, Bilbao, and Departments of Radiologic Surgery and Physical Medicine, University of Basque Country, Vizcaya, Spain (LA-C).
authors.forename: Ignacio
authors.initials: I
authors.lastname: Armendáriz-Buil
authors.forename: Félix
authors.initials: F
authors.lastname: Lobato-Solores
authors.forename: Luciano
authors.initials: L
authors.lastname: Aguilera-Celorrio
authors.forename: Emilio
authors.initials: E
authors.lastname: Morros-Díaz
authors.forename: Enrique
authors.initials: E
authors.lastname: Fraile-Jiménez
authors.forename: Jorge
authors.initials: J
authors.lastname: Vera-Bella
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000732:Androstanols / Q000009:adverse effects*; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D016343:Monitoring, Intraoperative; D019148:Neuromuscular Blockade / Q000009:adverse effects*; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects*; D011446:Prospective Studies; D000077123:Rocuronium
chemical_list: D000732:Androstanols; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D003473:Neuromuscular Nondepolarizing Agents; D000077123:Rocuronium